Daniel Speiser

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


313 publications

2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | ...
 
Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding.
Spodzieja M., Kuncewicz K., Sieradzan A., Karczyńska A., Iwaszkiewicz J., Cesson V., Węgrzyn K., Zhukov I., Maszota-Zieleniak M., Michielin O. et al., 2020/01/18. International journal of molecular sciences, 21 (2). Peer-reviewed.
 
Analysis of cancer cell-intrinsic immune regulation in response to CD8+ T cell attack.
Neubert N.J., Tillé L., Martignier C., Fuertes Marraco S.A., Speiser D.E., 2020. Methods in enzymology, 631 pp. 443-466. Peer-reviewed.
 
Virus-like particles for vaccination against cancer.
Mohsen M.O., Speiser D.E., Knuth A., Bachmann M.F., 2020/01. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology, 12 (1) pp. e1579. Peer-reviewed.
 
Murine CD8 T Cell Functional Avidity is Stable In Vivo but not In Vitro: Independence from Homologous Prime/Boost Time Interval and Antigen Density.
Gilfillan C.B., Wang C., Mohsen M.O., Rufer N., Hebeisen M., Allard M., Verdeil G., Irvine D.J., Bachmann M.F., Speiser D.E., 2019/11/30. European Journal of Immunology, 161 pp. 594-10. Peer-reviewed.
 
Defining 'T cell exhaustion'.
Blank C.U., Haining W.N., Held W., Hogan P.G., Kallies A., Lugli E., Lynn R.C., Philip M., Rao A., Restifo N.P. et al., 2019/11. Nature reviews. Immunology, 19 (11) pp. 665-674. Peer-reviewed.
 
Intratumoral CD8<sup>+</sup> T cells with stem cell-like properties: Implications for cancer immunotherapy.
Held W., Siddiqui I., Schaeuble K., Speiser D.E., 2019/10/23. Science translational medicine, 11 (515). Peer-reviewed.
 
Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8<sup>+</sup> T cells.
Mastelic-Gavillet B., Navarro Rodrigo B., Décombaz L., Wang H., Ercolano G., Ahmed R., Lozano L.E., Ianaro A., Derré L., Valerio M. et al., 2019/10/10. Journal for immunotherapy of cancer, 7 (1) p. 257. Peer-reviewed.
 
Biomodulina T partially restores immunosenescent CD4 and CD8 T cell compartments in the elderly.
Saavedra D., Fuertes S.A., Suárez G.M., González A., Lorenzo-Luaces P., García B., Aznar E., Mazorra Z., Crombet T., Speiser D.E. et al., 2019/09. Experimental gerontology, 124 p. 110633. Peer-reviewed.
 
High-throughput Screening of Human Tumor Antigen-specific CD4 T Cells, Including Neoantigen-reactive T Cells.
Costa-Nunes C., Cachot A., Bobisse S., Arnaud M., Genolet R., Baumgaertner P., Speiser D.E., Sousa Alves P.M., Sandoval F., Adotévi O. et al., 2019/07/15. Clinical cancer research, 25 (14) pp. 4320-4331. Peer-reviewed.
 
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.
Berner F., Bomze D., Diem S., Ali O.H., Fässler M., Ring S., Niederer R., Ackermann C.J., Baumgaertner P., Pikor N. et al., 2019/07/01. JAMA oncology, 5 (7) pp. 1043-1047. Peer-reviewed.
 
Attenuation of chronic antiviral T-cell responses through constitutive COX2-dependent prostanoid synthesis by lymph node fibroblasts.
Schaeuble K., Cannelle H., Favre S., Huang H.Y., Oberle S.G., Speiser D.E., Zehn D., Luther S.A., 2019/07. PLoS biology, 17 (7) pp. e3000072. Peer-reviewed.
 
MicroRNA-155 Expression Is Enhanced by T-cell Receptor Stimulation Strength and Correlates with Improved Tumor Control in Melanoma.
Martinez-Usatorre A., Sempere L.F., Carmona S.J., Carretero-Iglesia L., Monnot G., Speiser D.E., Rufer N., Donda A., Zehn D., Jandus C. et al., 2019/06. Cancer immunology research, 7 (6) pp. 1013-1024. Peer-reviewed.
 
Correction to: Vaccination with nanoparticles combined with micro-adjuvants protects against cancer.
Mohsen M.O., Heath M.D., Cabral-Miranda G., Lipp C., Zeltins A., Sande M., Stein J.V., Riether C., Roesti E., Zha L. et al., 2019/05/23..
 
Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients.
Broggi MAS, Maillat L., Clement C.C., Bordry N., Corthésy P., Auger A., Matter M., Hamelin R., Potin L., Demurtas D. et al., 2019/05/06. The Journal of experimental medicine, 216 (5) pp. 1091-1107. Peer-reviewed.
Vaccination with nanoparticles combined with micro-adjuvants protects against cancer.
Mohsen M.O., Heath M.D., Cabral-Miranda G., Lipp C., Zeltins A., Sande M., Stein J.V., Riether C., Roesti E., Zha L. et al., 2019/04/26. Journal for immunotherapy of cancer, 7 (1) p. 114. Peer-reviewed.
 
Maf deficiency in T cells dysregulates T<sub>reg</sub> - T<sub>H</sub>17 balance leading to spontaneous colitis.
Imbratta C., Leblond M.M., Bouzourène H., Speiser D.E., Velin D., Verdeil G., 2019/04/16. Scientific reports, 9 (1) p. 6135. Peer-reviewed.
 
Publisher Correction: Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle.
Cheng W.C., Tsui Y.C., Ragusa S., Koelzer V.H., Mina M., Franco F., Läubli H., Tschumi B., Speiser D., Romero P. et al., 2019/04..
Circulating CD56<sup>bright</sup> NK cells inversely correlate with survival of melanoma patients.
de Jonge K., Ebering A., Nassiri S., Maby-El Hajjami H., Ouertatani-Sakouhi H., Baumgaertner P., Speiser D.E., 2019/03/14. Scientific reports, 9 (1) p. 4487. Peer-reviewed.
 
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients.
Fässler M., Diem S., Mangana J., Hasan Ali O., Berner F., Bomze D., Ring S., Niederer R., Del Carmen Gil Cruz C., Pérez Shibayama C.I. et al., 2019/02/20. Journal for immunotherapy of cancer, 7 (1) p. 50. Peer-reviewed.
 
Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle.
Cheng W.C., Tsui Y.C., Ragusa S., Koelzer V.H., Mina M., Franco F., Läubli H., Tschumi B., Speiser D., Romero P. et al., 2019/02. Nature immunology, 20 (2) pp. 206-217. Peer-reviewed.
Intratumoral Tcf1<sup>+</sup>PD-1<sup>+</sup>CD8<sup>+</sup> T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy.
Siddiqui I., Schaeuble K., Chennupati V., Fuertes Marraco S.A., Calderon-Copete S., Pais Ferreira D., Carmona S.J., Scarpellino L., Gfeller D., Pradervand S. et al., 2019/01/15. Immunity, 50 (1) pp. 195-211.e10. Peer-reviewed.
 
A structural model of the immune checkpoint CD160-HVEM complex derived from HDX-mass spectrometry and molecular modeling.
Kuncewicz K., Spodzieja M., Sieradzan A., Karczyńska A., Dąbrowska K., Dadlez M., Speiser D.E., Derre L., Rodziewicz-Motowidło S., 2019/01/11. Oncotarget, 10 (4) pp. 536-550. Peer-reviewed.
 
High Peptide Dose Vaccination Promotes the Early Selection of Tumor Antigen-Specific CD8 T-Cells of Enhanced Functional Competence.
Carretero-Iglesia L., Couturaud B., Baumgaertner P., Schmidt J., Maby-El Hajjami H., Speiser D.E., Hebeisen M., Rufer N., 2019. Frontiers in immunology, 10 p. 3016. Peer-reviewed.
 
Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine.
Mohsen M.O., Vogel M., Riether C., Muller J., Salatino S., Ternette N., Gomes A.C., Cabral-Miranda G., El-Turabi A., Ruedl C. et al., 2019. Frontiers in immunology, 10 p. 1015. Peer-reviewed.
 
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.
Stanczak M.A., Siddiqui S.S., Trefny M.P., Thommen D.S., Boligan K.F., von Gunten S., Tzankov A., Tietze L., Lardinois D., Heinzelmann-Schwarz V. et al., 2018/11/01. The Journal of clinical investigation, 128 (11) pp. 4912-4923. Peer-reviewed.
 
Human TSCM cell dynamics in vivo are compatible with long-lived immunological memory and stemness.
Costa Del Amo P., Lahoz-Beneytez J., Boelen L., Ahmed R., Miners K.L., Zhang Y., Roger L., Jones R.E., Marraco SAF, Speiser D.E. et al., 2018/06. PLoS biology, 16 (6) pp. e2005523. Peer-reviewed.
The C-terminal extension landscape of naturally presented HLA-I ligands.
Guillaume P., Picaud S., Baumgaertner P., Montandon N., Schmidt J., Speiser D.E., Coukos G., Bassani-Sternberg M., Filippakopoulos P., Gfeller D., 2018/05/15. Proceedings of the National Academy of Sciences of the United States of America, 115 (20) pp. 5083-5088. Peer-reviewed.
 
T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.
Neubert N.J., Schmittnaegel M., Bordry N., Nassiri S., Wald N., Martignier C., Tillé L., Homicsko K., Damsky W., Maby-El Hajjami H. et al., 2018/04/11. Science translational medicine, 10 (436). Peer-reviewed.
T cell receptor alpha variable 12-2 bias in the immunodominant response to Yellow fever virus.
Bovay A., Zoete V., Dolton G., Bulek A.M., Cole D.K., Rizkallah P.J., Fuller A., Beck K., Michielin O., Speiser D.E. et al., 2018/02. European journal of immunology, 48 (2) pp. 258-272. Peer-reviewed.
Lymphatic vessel density is associated with CD8<sup>+</sup> T cell infiltration and immunosuppressive factors in human melanoma.
Bordry N., Broggi MAS, de Jonge K., Schaeuble K., Gannon P.O., Foukas P.G., Danenberg E., Romano E., Baumgaertner P., Fankhauser M. et al., 2018. Oncoimmunology, 7 (8) pp. e1462878. Peer-reviewed.
 
Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease.
Diem S., Hasan Ali O., Ackermann C.J., Bomze D., Koelzer V.H., Jochum W., Speiser D.E., Mertz K.D., Flatz L., 2018/01. Cancer immunology, immunotherapy, 67 (1) pp. 39-45. Peer-reviewed.
Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data.
Racle J., de Jonge K., Baumgaertner P., Speiser D.E., Gfeller D., 2017/11/13. eLife, 6 pp. 1-25. Peer-reviewed.
 
More T Cells versus Better T Cells in Patients with Breast Cancer.
Speiser D.E., Verdeil G., 2017/10. Cancer discovery, 7 (10) pp. 1062-1064. Peer-reviewed.
 
Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma.
Fankhauser M., Broggi MAS, Potin L., Bordry N., Jeanbart L., Lund A.W., Da Costa E., Hauert S., Rincon-Restrepo M., Tremblay C. et al., 2017/09/13. Science translational medicine, 9 (407) pp. 1-13. Peer-reviewed.
TCR-ligand dissociation rate is a robust and stable biomarker of CD8+ T cell potency.
Allard M., Couturaud B., Carretero-Iglesia L., Duong M.N., Schmidt J., Monnot G.C., Romero P., Speiser D.E., Hebeisen M., Rufer N., 2017/07/20. JCI insight, 2 (14) pp. e92570. Peer-reviewed.
Rapid and Continued T-Cell Differentiation into Long-term Effector and Memory Stem Cells in Vaccinated Melanoma Patients.
Gannon P.O., Baumgaertner P., Huber A., Iancu E.M., Cagnon L., Abed Maillard S., Maby-El Hajjami H., Speiser D.E., Rufer N., 2017/07/01. Clinical cancer research, 23 (13) pp. 3285-3296. Peer-reviewed.
Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer.
Chevalier M.F., Bohner P., Pieraerts C., Lhermitte B., Gourmaud J., Nobile A., Rotman S., Cesson V., Martin V., Legris A.S. et al., 2017/06. European urology, 71 (6) pp. 854-857. Peer-reviewed.
 
Broad and Conserved Immune Regulation by Genetically Heterogeneous Melanoma Cells.
Neubert N.J., Tillé L., Barras D., Soneson C., Baumgaertner P., Rimoldi D., Gfeller D., Delorenzi M., Fuertes Marraco S.A., Speiser D.E., 2017/04/01. Cancer research, 77 (7) pp. 1623-1636. Peer-reviewed.
Heterogeneity assessment of functional T cell avidity.
Ioannidou K., Baumgaertner P., Gannon P.O., Speiser M.F., Allard M., Hebeisen M., Rufer N., Speiser D.E., 2017/03/13. Scientific reports, 7 p. 44320. Peer-reviewed.
 
Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L., Cesson V., Lucca I., Cerantola Y., Valerio M., Fritschi U., Vlamopoulos Y., Burruni R., Legris A.S., Dartiguenave F. et al., 2017/02/01. Clinical cancer research, 23 (3) pp. 717-725. Peer-reviewed.
 
T memory stem cells in health and disease.
Gattinoni L., Speiser D.E., Lichterfeld M., Bonini C., 2017/01/06. Nature medicine, 23 (1) pp. 18-27. Peer-reviewed.
Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.
Spodzieja M., Lach S., Iwaszkiewicz J., Cesson V., Kalejta K., Olive D., Michielin O., Speiser D.E., Zoete V., Derré L. et al., 2017. PloS one, 12 (6) pp. e0179201.
ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence.
Chevalier M.F., Trabanelli S., Racle J., Salomé B., Cesson V., Gharbi D., Bohner P., Domingos-Pereira S., Dartiguenave F., Fritschi A.S. et al., 2017. The Journal of Clinical Investigation, 127 (8) pp. 2916-2929. Peer-reviewed.
Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing.
Royer-Bertrand B., Torsello M., Rimoldi D., El Zaoui I., Cisarova K., Pescini-Gobert R., Raynaud F., Zografos L., Schalenbourg A., Speiser D. et al., 2016/11/03. American journal of human genetics, 99 (5) pp. 1190-1198. Peer-reviewed.
 
Magnetic nanoparticle-induced hyperthermia with appropriate payloads: Paul Ehrlich's "magic (nano)bullet" for cancer theranostics?
Datta N.R., Krishnan S., Speiser D.E., Neufeld E., Kuster N., Bodis S., Hofmann H., 2016/11. Cancer treatment reviews, 50 pp. 217-227. Peer-reviewed.
A Well-Controlled Experimental System to Study Interactions of Cytotoxic T Lymphocytes with Tumor Cells.
Neubert N.J., Soneson C., Barras D., Baumgaertner P., Rimoldi D., Delorenzi M., Fuertes Marraco S.A., Speiser D.E., 2016/08. Frontiers In Immunology, 7 p. 326. Peer-reviewed.
 
Identification of melanoma cells and lymphocyte subpopulations in lymph node metastases by FTIR imaging histopathology.
Wald N., Bordry N., Foukas P.G., Speiser D.E., Goormaghtigh E., 2016/02. Biochimica et biophysica acta, 1862 (2) pp. 202-212. Peer-reviewed.
 
Anticancer Teamwork: Cross-Presenting Dendritic Cells Collaborate with Therapeutic Monoclonal Antibodies.
Robert-Tissot C., Speiser D.E., 2016. Cancer Discovery, 6 (1) pp. 17-19.
 
Anticancer Teamwork: Cross-Presenting Dendritic Cells Collaborate with Therapeutic Monoclonal Antibodies.
Robert-Tissot C., Speiser D.E., 2016. Cancer Discovery, 6 (1) pp. 17-19. Peer-reviewed.
 
Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer.
Hasan Ali O., Diem S., Markert E., Jochum W., Kerl K., French L.E., Speiser D.E., Früh M., Flatz L., 2016. Oncoimmunology, 5 (11) pp. e1231292. Peer-reviewed.
 
From T cell “exhaustion” to anti-cancer immunity
Verdeil Grégory, Fuertes Marraco Silvia A., Murray Timothy, Speiser Daniel E., 2016/01. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1865 (1) pp. 49-57. Peer-reviewed.
 
Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
Diem S., Keller F., Rüesch R., Maillard S.A., Speiser D.E., Dummer R., Siano M., Urner-Bloch U., Goldinger S.M., Flatz L., 2016. Journal of immunotherapy, 39 (9) pp. 379-382. Peer-reviewed.
 
Regulatory circuits of T cell function in cancer.
Speiser D.E., Ho P.C., Verdeil G., 2016. Nature Reviews. Immunology, 16 (10) pp. 599-611. Peer-reviewed.
Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8(+) and CD4(+) T-cell responses with multiple specificities including a novel DR7-restricted epitope.
Baumgaertner P., Costa Nunes C., Cachot A., Maby-El Hajjami H., Cagnon L., Braun M., Derré L., Rivals J.P., Rimoldi D., Gnjatic S. et al., 2016. Oncoimmunology, 5 (10) pp. e1216290. Peer-reviewed.
Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients-Report of a Phase I/IIa Clinical Trial.
Legat A., Maby-El Hajjami H., Baumgaertner P., Cagnon L., Abed Maillard S., Geldhof C., Iancu E.M., Lebon L., Guillaume P., Dojcinovic D. et al., 2016. Clinical Cancer Research, 22 (6) pp. 1330-1340. Peer-reviewed.
Very Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates with Survival of Melanoma Patients.
Murray T., Fuertes Marraco S.A., Baumgaertner P., Bordry N., Cagnon L., Donda A., Romero P., Verdeil G., Speiser D.E., 2016. Frontiers in immunology, 7 p. 573. Peer-reviewed.
29 th Annual meeting of the Society for Immunotherapy of Cancer (SITC)
Hurwitz A.A., Lee S., Knox S., Kohrt H., Verdeil G., Romano E., Margolin K., Urba W.J., Speiser D.E., 2015. Journal For Immunotherapy of Cancer, 3 p. 0.
 
A01: Associations of lymphangiogenesis with immune profiles of melanoma patients
Bordry N., Gannon P., Foukas P., Letovanec I., Meyer C., Legat A., Yan P., Romano E., Swartz M., Speiser D., 2015. pp. - dans AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment, Cancer Research. Peer-reviewed.
 
An infrared spectral signature of human lymphocyte subpopulations from peripheral blood.
Wald N., Legat A., Meyer C., Speiser D.E., Goormaghtigh E., 2015. Analyst, 140 (7) pp. 2257-2265. Peer-reviewed.
 
Consensus nomenclature for CD8 + T cell phenotypes in cancer
Apetoh L., Smyth M.J., Drake C.G., Abastado J.P., Apte R.N., Ayyoub M., Blay J.Y., Bonneville M., Butterfield L.H., Caignard A. et al., 2015. Oncoimmunology, 4 (4) pp. e998538. Peer-reviewed.
Genome-wide RNA profiling of long-lasting stem cell-like memory CD8 T cells induced by Yellow Fever vaccination in humans.
Fuertes Marraco S.A., Soneson C., Delorenzi M., Speiser D.E., 2015. Genomics Data, 5 pp. 297-301. Peer-reviewed.
 
High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools.
Chevalier M.F., Bobisse S., Costa-Nunes C., Cesson V., Jichlinski P., Speiser D.E., Harari A., Coukos G., Romero P., Nardelli-Haefliger D. et al., 2015. Oncoimmunology, 4 (10) pp. e1029702. Peer-reviewed.
Identification of Rare High-Avidity, Tumor-Reactive CD8+ T Cells by Monomeric TCR-Ligand Off-Rates Measurements on Living Cells.
Hebeisen M., Schmidt J., Guillaume P., Baumgaertner P., Speiser D.E., Luescher I., Rufer N., 2015. Cancer Research, 75 (10) pp. 1983-1991. Peer-reviewed.
Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens.
Hebeisen M., Allard M., Gannon P.O., Schmidt J., Speiser D.E., Rufer N., 2015. Frontiers in Immunology, 6 p. 582. Peer-reviewed.
 
Inhibitory Receptors Beyond T Cell Exhaustion
Fuertes Marraco Silvia A., Neubert Natalie J., Verdeil Grégory, Speiser Daniel E., 2015. Frontiers in Immunology, 6 (17) pp. 1639-1641.
Inhibitory Receptors Beyond T Cell Exhaustion.
Fuertes Marraco S.A., Neubert N.J., Verdeil G., Speiser D.E., 2015. Frontiers in Immunology, 6 p. 310. Peer-reviewed.
 
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.
Romano E., Kusio-Kobialka M., Foukas P.G., Baumgaertner P., Meyer C., Ballabeni P., Michielin O., Weide B., Romero P., Speiser D.E., 2015. Proceedings of the National Academy of Sciences of the United States of America, 112 (19) pp. 6140-6145.
Long-lasting stem cell-like memory CD8+ T cells with a naïve-like profile upon yellow fever vaccination.
Fuertes Marraco S.A., Soneson C., Cagnon L., Gannon P.O., Allard M., Maillard S.A., Montandon N., Rufer N., Waldvogel S., Delorenzi M. et al., 2015. Science Translational Medicine, 7 (282) pp. 282ra48. Peer-reviewed.
 
Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion.
Giordano M., Henin C., Maurizio J., Imbratta C., Bourdely P., Buferne M., Baitsch L., Vanhille L., Sieweke M.H., Speiser D.E. et al., 2015. EMBO Journal, 34 (15) pp. 2042-2058. Peer-reviewed.
 
Quantitative TCR:pMHC Dissociation Rate Assessment by NTAmers Reveals Antimelanoma T Cell Repertoires Enriched for High Functional Competence.
Gannon P.O., Wieckowski S., Baumgaertner P., Hebeisen M., Allard M., Speiser D.E., Rufer N., 2015. Journal of Immunology, 195 (1) pp. 356-366. Peer-reviewed.
STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Demaria O., De Gassart A., Coso S., Gestermann N., Di Domizio J., Flatz L., Gaide O., Michielin O., Hwu P., Petrova T.V. et al., 2015. Proceedings of the National Academy of Sciences of the United States of America, 112 (50) pp. 15408-15413.
 
5P * MICROTUBULE-DEPOLYMERIZING AGENTS USED IN ANTIBODY-DRUG-CONJUGATES INDUCE ANTITUMOR ACTIVITY BY STIMULATION OF DENDRITIC CELLS
Speiser D. (eds.), 2014/11/01., 25 suppl 6 1, Oxford University Press (OUP).
 
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.
Kvistborg P., Philips D., Kelderman S., Hageman L., Ottensmeier C., Joseph-Pietras D., Welters M.J., van der Burg S., Kapiteijn E., Michielin O. et al., 2014. Science Translational Medicine, 6 (254) pp. 254ra128. Peer-reviewed.
 
Cancer immunotherapy drives implementation science in oncology.
Speiser D.E., Flatz L., 2014. Human Vaccines and Immunotherapeutics, 10 (11) pp. 3107-3110.
Classification of current anticancer immunotherapies.
Galluzzi L., Vacchelli E., Bravo-San Pedro J.M., Buqué A., Senovilla L., Baracco E.E., Bloy N., Castoldi F., Abastado J.P., Agostinis P. et al., 2014. Oncotarget, 5 (24) pp. 12472-12508.
Deciphering the unusual HLA-A2/Melan-A/MART-1-specific TCR repertoire in humans.
Romero P., Speiser D.E., Rufer N., 2014. European Journal of Immunology, 44 (9) pp. 2567-2570. Peer-reviewed.
Development of a T Cell Receptor Targeting an HLA-A*0201 Restricted Epitope from the Cancer-Testis Antigen SSX2 for Adoptive Immunotherapy of Cancer.
Abate-Daga D., Speiser D.E., Chinnasamy N., Zheng Z., Xu H., Feldman S.A., Rosenberg S.A., Morgan R.A., 2014. Plos One, 9 (3) pp. e93321. Peer-reviewed.
 
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.
Meyer C., Cagnon L., Costa-Nunes C.M., Baumgaertner P., Montandon N., Leyvraz L., Michielin O., Romano E., Speiser D.E., 2014. Cancer Immunology, Immunotherapy : Cii, 63 (3) pp. 247-257. Peer-reviewed.
IRF4 and BATF are critical for CD8(+) T-cell function following infection with LCMV.
Grusdat M., McIlwain D.R., Xu H.C., Pozdeev V.I., Knievel J., Crome S.Q., Robert-Tissot C., Dress R.J., Pandyra A.A., Speiser D.E. et al., 2014. Cell Death and Differentiation, 21 (7) pp. 1050-1060. Peer-reviewed.
MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial.
Romano E., Michielin O., Voelter V., Laurent J., Bichat H., Stravodimou A., Romero P., Speiser D.E., Triebel F., Leyvraz S. et al., 2014. Journal of Translational Medicine, 12 p. 97.
 
Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells.
Müller P., Martin K., Theurich S., Schreiner J., Savic S., Terszowski G., Lardinois D., Heinzelmann-Schwarz V.A., Schlaak M., Kvasnicka H.M. et al., 2014. Cancer Immunology Research, 2 (8) pp. 741-755. Peer-reviewed.
 
Pulmonary Sarcoid-like Granulomatosis after Multiple Vaccinations of a Long-term Surviving Patient with Metastatic Melanoma.
Bordry N., Costa-Nunes C.M., Cagnon L., Gannon P.O., Abed-Maillard S., Baumgaertner P., Murray T., Letovanec I., Lazor R., Bouchaab H. et al., 2014. Cancer Immunology Research, 2 (12) pp. 1148-1153.
 
T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?
Speiser D.E., Utzschneider D.T., Oberle S.G., Münz C., Romero P., Zehn D., 2014. Nature Reviews. Immunology, 14 (11) pp. 768-774.
 
A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours.
Gillessen S., Gnad-Vogt U.S., Gallerani E., Beck J., Sessa C., Omlin A., Mattiacci M.R., Liedert B., Kramer D., Laurent J. et al., 2013. European Journal of Cancer, 49 (1) pp. 35-44.
 
Breast cancer and melanoma cell line identification by FTIR imaging after formalin-fixation and paraffin-embedding.
Verdonck M., Wald N., Janssis J., Yan P., Meyer C., Legat A., Speiser D.E., Desmedt C., Larsimont D., Sotiriou C. et al., 2013. Analyst, 138 (14) pp. 4083-4091.
CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses.
Corgnac S., Perret R., Derré L., Zhang L., Stirnemann K., Zauderer M., Speiser D.E., Mach J.P., Romero P., Donda A., 2013. Cancer Immunology, Immunotherapy, 62 (4) pp. 747-760.
 
Clinical Implications of CD8+ T-cell infiltration in frequent and rare cancers.
Feldmeyer L., Gaide O., Speiser D.E., 2013. Journal of Investigative Dermatology, 133 (8) pp. 1929-1932.
CpG-ODN-induced sustained expression of BTLA mediating selective inhibition of human B cells.
Thibult M.L., Rivals J.P., Mamessier E., Gertner-Dardenne J., Pastor S., Speiser D.E., Derré L., Olive D., 2013. Journal of Molecular Medicine, 91 (2) pp. 195-205.
Cysteine-rich Domain 1 of CD40 Mediates Receptor Self-assembly.
Smulski C.R., Beyrath J., Decossas M., Chekkat N., Wolff P., Estieu-Gionnet K., Guichard G., Speiser D., Schneider P., Fournel S., 2013. Journal of Biological Chemistry, 288 (15) pp. 10914-10922.
 
Hit parade for adoptive cell transfer therapy: the best T cells for superior clinical responses.
Speiser D.E., 2013. Cancer Discovery, 3 (4) pp. 379-381.
 
Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression.
Romano E., Pradervand S., Paillusson A., Weber J., Harshman K., Muehlethaler K., Speiser D., Peters S., Rimoldi D., Michielin O., 2013. Clinical Cancer Research, 19 (20) pp. 5749-5757.
Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than "Exhaustion" of Human CD8 T Cells.
Legat A., Speiser D.E., Pircher H., Zehn D., Fuertes Marraco S.A., 2013. Frontiers in Immunology, 4 p. 455.
 
Mobilizing and evaluating anticancer T cells: pitfalls and solutions.
Robert-Tissot C., Nguyen L.T., Ohashi P.S., Speiser D.E., 2013. Expert Review of Vaccines, 12 (11) pp. 1325-1340.
Molecular insights for optimizing T cell receptor specificity against cancer.
Hebeisen M., Oberle S.G., Presotto D., Speiser D.E., Zehn D., Rufer N., 2013. Frontiers In Immunology, 4 p. 154.
Persistence of EBV Antigen-Specific CD8 T Cell Clonotypes during Homeostatic Immune Reconstitution in Cancer Patients.
Iancu E.M., Gannon P.O., Laurent J., Gupta B., Romero P., Michielin O., Romano E., Speiser D.E., Rufer N., 2013. Plos One, 8 (10) pp. e78686.
Prediction of cross-recognition of peptide-HLA A2 by Melan-A-specific cytotoxic T lymphocytes using three-dimensional quantitative structure-activity relationships.
Fagerberg T., Zoete V., Viatte S., Baumgaertner P., Alves P.M., Romero P., Speiser D.E., Michielin O., 2013. PLoS One, 8 (7) pp. e65590.
 
Prognostic value of arginase-II expression and regulatory T-cell infiltration in head and neck squamous cell carcinoma.
Bron L., Jandus C., Andrejevic-Blant S., Speiser D.E., Monnier P., Romero P., Rivals J.P., 2013. International Journal of Cancer. Journal International Du Cancer, 132 (3) pp. E85-E93.
Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients.
Buchegger F., Larson S.M., Mach J.P., Chalandon Y., Dietrich P.Y., Cairoli A., Prior J.O., Romero P., Speiser D.E., 2013. Clinical and Developmental Immunology, 2013 p. 875343.
SHP-1 phosphatase activity counteracts increased T cell receptor affinity.
Hebeisen M., Baitsch L., Presotto D., Baumgaertner P., Romero P., Michielin O., Speiser D.E., Rufer N., 2013. Journal of Clinical Investigation, 123 (3) pp. 1044-1056.
 
T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion.
Utzschneider D.T., Legat A., Fuertes Marraco S.A., Carrié L., Luescher I., Speiser D.E., Zehn D., 2013. Nature Immunology, 14 (6) pp. 603-610.
T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein.
Laurent J., Touvrey C., Gillessen S., Joffraud M., Vicari M., Bertrand C., Ongarello S., Liedert B., Gallerani E., Beck J. et al., 2013. Journal of Translational Medicine, 11 (5) pp. 1-12.
A molecular profile of T-cell exhaustion in cancer.
Speiser D.E., 2012. Oncoimmunology, 1 (3) pp. 369-371. Peer-reviewed.
 
A stepwise protocol to coat aAPC beads prevents out-competition of anti-CD3 mAb and consequent experimental artefacts.
Fuertes Marraco S.A., Baumgaertner P., Legat A., Rufer N., Speiser D.E., 2012. Journal of Immunological Methods, 385 (1-2) pp. 90-95.
 
Conference scene: Immune signatures in the tumor and beyond.
Kandalaft L.E., Kalos M., Melief C.J., Speiser D.E., Coukos G., 2012. Immunotherapy, 4 (8) pp. 761-772.
Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific cytotoxic T lymphocytes after vaccination with low peptide dose.
Lövgren T., Baumgaertner P., Wieckowski S., Devêvre E., Guillaume P., Luescher I., Rufer N., Speiser D.E., 2012. Cancer Immunology, Immunotherapy, 61 (6) pp. 817-826.
 
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
Nikolaev S.I., Rimoldi D., Iseli C., Valsesia A., Robyr D., Gehrig C., Harshman K., Guipponi M., Bukach O., Zoete V. et al., 2012. Nature Genetics, 44 (2) pp. 133-139.
Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization.
Baitsch L., Legat A., Barba L., Fuertes Marraco S.A., Rivals J.P., Baumgaertner P., Christiansen-Jucht C., Bouzourene H., Rimoldi D., Pircher H. et al., 2012. PLoS One, 7 (2) pp. e30852.
 
Human CD8(+) T cells engineered with supraphysiological TCRs are functionally inhibited via PD-1 and SHP-1 phosphatase
Hebeisen M., Baitsch L., Presotto D., Baumgaertner P., Romero P., Michielin O., Speiser D. E., Rufer N., 2012. p. 713 dans European Congress of Immunology, Immunology.
Human melanoma-specific CD8(+) T-cells from metastases are capable of antigen-specific degranulation and cytolysis directly ex vivo.
Mahnke Y.D., Devevre E., Baumgaertner P., Matter M., Rufer N., Romero P., Speiser D.E., 2012. Oncoimmunology, 1 (4) pp. 467-530. Peer-reviewed.
 
Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness.
Irving M., Zoete V., Hebeisen M., Schmid D., Baumgartner P., Guillaume P., Romero P., Speiser D., Luescher I., Rufer N. et al., 2012. Journal of Biological Chemistry, 287 (27) pp. 23068-23078. Peer-reviewed.
 
Melanoma vaccines
Romero P., Speiser D.E., 2012. pp. 207-232 dans Gajewski T.F., Hodi F.S. (eds.) Targeted Therapeutics in Melanoma, Springer.
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.
Goldinger S.M., Dummer R., Baumgaertner P., Mihic-Probst D., Schwarz K., Hammann-Haenni A., Willers J., Geldhof C., Prior J.O., Kündig T.M. et al., 2012. European Journal of Immunology, 42 (11) pp. 3049-3061.
 
Pulmonary sarcoid-like granulomatosis induced by ipilimumab.
Berthod G., Lazor R., Letovanec I., Romano E., Noirez L., Mazza Stalder J., Speiser D.E., Peters S., Michielin O., 2012. Journal of Clinical Oncology, 30 (17) pp. e156-e159.
Simultaneous coexpression of memory-related and effector-related genes by individual human CD8 T cells depends on antigen specificity and differentiation.
Gupta B., Iancu E.M., Gannon P.O., Wieckowski S., Baitsch L., Speiser D.E., Rufer N., 2012. Journal of Immunotherapy, 35 (6) pp. 488-501.
The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy.
Pasero C., Speiser D.E., Derré L., Olive D., 2012. Current Opinion in Pharmacology, 12 (4) pp. 478-485.
 
The three main stumbling blocks for anticancer T cells.
Baitsch L., Fuertes-Marraco S.A., Legat A., Meyer C., Speiser D.E., 2012. Trends in Immunology, 33 (7) pp. 364-372.
Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells.
Baumgaertner P., Jandus C., Rivals J.P., Derré L., Lövgren T., Baitsch L., Guillaume P., Luescher I.F., Berthod G., Matter M. et al., 2012. International Journal of Cancer. Journal International Du Cancer, 130 (11) pp. 2607-2617.
 
Virus-like particles induce robust human T-helper cell responses.
Braun M., Jandus C., Maurer P., Hammann-Haenni A., Schwarz K., Bachmann M.F., Speiser D.E., Romero P., 2012. European Journal of Immunology, 42 (2) pp. 330-340.
 
Combined clonotyping and gene signatures of individual tumor-reactive CD8 T-cells define their functional relevance following peptide vaccination in melanoma patients
Gupta B., Wieckowski S., Iancu M., Romero P., Speiser D.E., Rufer N., 2011. pp. 110-110 dans Annual Congress SGAI-SSAI, Advances in immunology and allergology: from research to diagnosis and therapy, Allergologie. Peer-reviewed.
 
Correlation of tumor-associated antigens MAGE, NY-ESO-1 and P53 expression with clinical and pathological relationships of patients with oral squamous cell carcinoma
Rivals J.P., Sandu K., Andrejevic-Blant S., Rimoldi D., Speiser D., Romero P., Monnier P.H., Bron L., 2011. pp. 108-109 dans Annual Congress SGAI-SSAI, Advances in immunology and allergology: from research to diagnosis and therapy, Allergologie. Peer-reviewed.
Differentiation associated regulation of microRNA expression in vivo in human CD8+ T cell subsets.
Salaun B., Yamamoto T., Badran B., Tsunetsugu-Yokota Y., Roux A., Baitsch L., Rouas R., Fayyad-Kazan H., Baumgaertner P., Devevre E. et al., 2011. Journal of Translational Medicine, 9 p. 44.
 
Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific T cells after vaccination with low peptide dose
Loevgren T., Baumgaertner P., Wieckowski S., Devevre E., Guillaume P., Luescher I., Rufer N., Speiser D. E., 2011. pp. 109-110 dans -, Allergologie. Peer-reviewed.
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients.
Baitsch L., Baumgaertner P., Devêvre E., Raghav S.K., Legat A., Barba L., Wieckowski S., Bouzourene H., Deplancke B., Romero P. et al., 2011. Journal of Clinical Investigation, 121 (6) pp. 2350-2360.
 
Lymphodepletion by short-term chemotherapy does not alter the highly stable and persistent EBV specific CD8 T cell repertoire
Iancu E.M., Laurent J., Wieckowski S., Gupta B., Leyvraz S., Meylan P., Romero P., Michelin O., Speiser D., Rufer N., 2011. pp. 101-102 dans Annual Congress SGAI-SSAI, Advances in immunology and allergology: from research to diagnosis and therapy, Allergologie. Peer-reviewed.
MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes.
Cesson V., Rivals J.P., Escher A., Piotet E., Thielemans K., Posevitz V., Dojcinovic D., Monnier P., Speiser D., Bron L. et al., 2011. Cancer Immunology, Immunotherapy, 60 (1) pp. 23-35.
 
Mélanome: une nouvette ère thérapeutique [Melanoma: a new therapeutic era].
Berthod G., Homicsko K., Bouchaab H., Matter M., Cerottini J.P., Guggisberg D., Speiser D., Leyvraz S., Michielin O., 2011. Revue Médicale Suisse, 7 (296) pp. 1126-1130.
 
Optimal CD8 T cell responsiveness is controlled within a defined TCR affinity window
Hebeisen M., Irving M., Schmid D., Zoete V., Romero P., Speiser D., Michielin O., Rufer N., 2011. p. 111 dans Annual Congress SGAI-SSAI, Advances in immunology and allergology: from research to diagnosis and therapy, Allergologie. Peer-reviewed.
 
Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma.
Cuffel C., Rivals J.P., Zaugg Y., Salvi S., Seelentag W., Speiser D.E., Liénard D., Monnier P., Romero P., Bron L. et al., 2011. International Journal of Cancer. Journal International du Cancer, 128 (11) pp. 2625-2634.
Profile of a serial killer: cellular and molecular approaches to study individual cytotoxic T-cells following therapeutic vaccination.
Iancu E.M., Baumgaertner P., Wieckowski S., Speiser D.E., Rufer N., 2011. Journal of Biomedicine and Biotechnology, 2011 p. 452606.
 
Reversible major histocompatibility complex I-peptide multimers containing Ni(2+)-nitrilotriacetic acid peptides and histidine tags improve analysis and sorting of CD8(+) T cells.
Schmidt J., Guillaume P., Irving M., Baumgaertner P., Speiser D., Luescher I.F., 2011. Journal of Biological Chemistry, 286 (48) pp. 41723-41735.
 
Single cell analysis reveals similar functional competence of dominant and non-dominant CD8 T-cell clonotypes
Rufer N., Wieckowski S., Gupta B., Iancu E., Baumgaertner P., Michielin O., Romero P., Speiser D., 2011. p. 108 dans Annual Congress SGAI-SSAI, Advances in immunology and allergology: from research to diagnosis and therapy, Allergologie. Peer-reviewed.
Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes.
Speiser D.E., Wieckowski S., Gupta B., Iancu E.M., Baumgaertner P., Baitsch L., Michielin O., Romero P., Rufer N., 2011. Proceedings of the National Academy of Sciences of the United States of America, 108 (37) pp. 15318-15323.
 
The CD4-like molecule LAG-3, biology and therapeutic applications.
Sierro S., Romero P., Speiser D.E., 2011. Expert Opinion On Therapeutic Targets, 15 (1) pp. 91-101. Peer-reviewed.
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.
Derré L., Rivals J.P., Jandus C., Pastor S., Rimoldi D., Romero P., Michielin O., Olive D., Speiser D.E., 2010. Journal of Clinical Investigation, 120 (1) pp. 157-167.
Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity.
Cervantes-Barragan L., Züst R., Maier R., Sierro S., Janda J., Levy F., Speiser D., Romero P., Rohrlich P.S., Ludewig B. et al., 2010. MBIO, 1 (4) pp. e00171-10.
 
Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function.
Schmid D.A., Irving M.B., Posevitz V., Hebeisen M., Posevitz-Fejfar A., Sarria J.C., Gomez-Eerland R., Thome M., Schumacher T.N., Romero P. et al., 2010. Journal of Immunology, 184 (9) pp. 4936-4946. Peer-reviewed.
Frequent MAGE mutations in human melanoma.
Caballero O.L., Zhao Q., Rimoldi D., Stevenson B.J., Svobodová S., Devalle S., Röhrig U.F., Pagotto A., Michielin O., Speiser D. et al., 2010. PLoS One, 5 (9) pp. e12773.
 
Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients.
Laurent J., Speiser D.E., Appay V., Touvrey C., Vicari M., Papaioannou A., Canellini G., Rimoldi D., Rufer N., Romero P. et al., 2010. Journal of Immunotherapy, 33 (7) pp. 723-734.
 
Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients.
Speiser D.E., Schwarz K., Baumgaertner P., Manolova V., Devevre E., Sterry W., Walden P., Zippelius A., Conzett K.B., Senti G. et al., 2010. Journal of Immunotherapy, 33 (8) pp. 848-858.
 
Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.
Speiser D.E., Romero P., 2010. Seminars in Immunology, 22 (3) pp. 144-154.
 
Novel soluble HLA-A2/MELAN-A complexes selectively stain a differentiation defective subpopulation of CD8+ T cells in patients with melanoma.
Guillaume P., Baumgaertner P., Neff L., Rufer N., Wettstein P., Speiser D.E., Luescher I.F., 2010. International Journal of Cancer, 127 (4) pp. 910-923. Peer-reviewed.
Quantitative multiparameter assays to measure the effect of adjuvants on human antigen-specific CD8 T-cell responses.
Derré L., Jandus C., Baumgaertner P., Posevitz V., Devêvre E., Romero P., Speiser D.E., 2010. Methods in Molecular Biology, 626 pp. 231-249.
 
Clonotype selection and composition of human CD8 T cells specific for persistent herpes viruses varies with differentiation but is stable over time.
Iancu E.M., Corthesy P., Baumgaertner P., Devevre E., Voelter V., Romero P., Speiser D.E., Rufer N., 2009/06. Journal of immunology, 183 (1) pp. 319-331. Peer-reviewed.
 
Dominant human CD8 T cell clonotypes persist simultaneously as memory and effector cells in memory phase.
Touvrey C., Derré L., Devevre E., Corthesy P., Romero P., Rufer N., Speiser D.E., 2009. Journal of Immunology, 182 (11) pp. 6718-6726. Peer-reviewed.
 
Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors.
Bricard G., Cesson V., Devevre E., Bouzourene H., Barbey C., Rufer N., Im J.S., Alves P.M., Martinet O., Halkic N. et al., 2009. Journal of Immunology, 182 (8) pp. 5140-5151.
 
Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients.
Wieckowski S., Baumgaertner P., Corthesy P., Voelter V., Romero P., Speiser D.E., Rufer N., 2009. Journal of Immunology, 183 (8) pp. 5397-5406.
 
Recent advances and hurdles in melanoma immunotherapy.
Jandus C., Speiser D., Romero P., 2009. Pigment cell & melanoma research, 22 (6) pp. 711-723. Peer-reviewed.
Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.
Jandus C., Bioley G., Dojcinovic D., Derré L., Baitsch L., Wieckowski S., Rufer N., Kwok W.W., Tiercy J.M., Luescher I.F. et al., 2009. Cancer Research, 69 (20) pp. 8085-8093. Peer-reviewed.
 
Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant.
Lienard D., Avril M.F., Le Gal F.A., Baumgaertner P., Vermeulen W., Blom A., Geldhof C., Rimoldi D., Pagliusi S., Romero P. et al., 2009. Journal of immunotherapy, 32 (8) pp. 875-883. Peer-reviewed.
 
An unusual case of metastatic melanoma sensitive to chemotherapy and immunotherapy, with late immune escape in the brain.
Voelter V., Pica A., Laurent J., Rimoldi D., Bouzourene H., Sajadi A., Matter M., Romero P., Rufer N., Speiser D.E., 2008. Cancer Immunity, 8 p. 6.
 
Analysis of naturally acquired CD4+T-cell responses to MAGE-A3 and MAGE-A4 cancer/testis antigens in patients with resected head and neck squamous cell carcinoma
Cesson V., Escher A., Piotet E., Rivals J. P., Speiser D., Bron L., Romero P., 2008. pp. 53S-53S dans Abstracts, Swiss Medical Weekly. Peer-reviewed.
 
Assessing ageing of individual T lymphocytes: Mission impossible?
Iancu Emanuela M., Speiser Daniel E., Rufer Nathalie, 2008. Mechanisms of Ageing and Development, 129 (1-2) pp. 67-78. Peer-reviewed.
 
Assessment of immune suppressive circuits in the tumour micro-environment of human head and neck squamous cell carcinoma (HNSCC)
Rivals J.P., Cesson V., Rimoldi D., Seelentag W., Speiser D., Romero P., Monnier P., Bron L., 2008. pp. 58S dans Annual Joint Meeting of the Swiss Societies for Pneumology, Paediatric Pneumology, Allergology and Immunology, Thoracic Surgery, Swiss Medical Weekly. Peer-reviewed.
Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues.
Derré L., Bruyninx M., Baumgaertner P., Ferber M., Schmid D., Leimgruber A., Zoete V., Romero P., Michielin O., Speiser D.E. et al., 2008. Proceedings of the National Academy of Sciences of the United States of America, 105 (39) pp. 15010-15015. Peer-reviewed.
 
Ex-vivo cytotoxic function by influenza specific CD8 effector T-cells from healthy humans in memory phase : P219
Touvrey C., Derre L., Rufer N., Romero P., Speiser D., 2008. pp. 50S-51S dans Annual Joint Meeting of the Swiss Societies for Pneumology, Paediatric Pneumology, Allergology and Immunology, Thoracic Surgery, Swiss Medical Weekly. Peer-reviewed.
 
Identification of tumor-associated antigens by large-scale analysis of genes expressed in human colorectal cancer.
Alves P.M., Lévy N., Stevenson B.J., Bouzourene H., Theiler G., Bricard G., Viatte S., Ayyoub M., Vuilleumier H., Givel J.C. et al., 2008. Cancer Immunity, 8 p. 11.
 
Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides
Jandus C., Bioley G., Rivals J.P., Dudler J., Speiser D., Romero P., 2008. Arthritis and Rheumatism, 58 (8) pp. 2307-2317. Peer-reviewed.
 
Nouveautés dans l'immunothérapie du cancer [New developments in cancer immunotherapy]
Michielin O., Rufer N., Romero P., Laurent J., Cerottini J.P., Gugisberg D., Leyvraz S., Speiser D., 2008. Revue Médicale Suisse, 4 (158) pp. 1248-1251.
 
RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses.
Schmitt M., Schmitt A., Rojewski M.T., Chen J., Giannopoulos K., Fei F., Yu Y., Götz M., Heyduk M., Ritter G. et al., 2008. Blood, 111 (3) pp. 1357-1365.
Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood
Jandus C., Bioley G., Speiser D.E., Romero P., 2008. Cancer Immunology, Immunotherapy, 57 (12) pp. 1795-1805. Peer-reviewed.
 
Tumour antigen specific CD8+T-cells from melanoma patients exert strong ex-vivo cytolytic activity
Mahnke Y., Devevre E., Baurngaertner P., Matter M., Rufer N., Rorner P., Speiser D., 2008. pp. 17S dans Annual Joint Meeting of the Swiss Societies for Pneumology, Paediatric Pneumology, Allergology and Immunology, Thoracic Surgery, Swiss Medical Weekly. Peer-reviewed.
 
Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen
Speiser D. E., Baumgaertner P., Voelter V., Devevre E., Barbey C., Rufer N., Romero P., 2008. Proceedings of the National Academy of Sciences of the United States of America, 105 (10) pp. 3849-3854. Peer-reviewed.
 
A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide.
Derré L., Ferber M., Touvrey C., Devevre E., Zoete V., Leimgruber A., Romero P., Michielin O., Lévy F., Speiser D.E., 2007/12/01. Journal of immunology, 179 (11) pp. 7635-7645. Peer-reviewed.
 
New approaches in metastatic melanoma: biological and molecular targeted therapies
Lejeune F. J., Rimoldi D., Speiser D., 2007/05. Expert Review of Anticancer Therapy, 7 (5) pp. 701-13.
A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide.
Derré L., Ferber M., Touvrey C., Devevre E., Zoete V., Leimgruber A., Romero P., Michielin O., Lévy F., Speiser D.E., 2007. Journal of Immunology, 179 (11) pp. 7635-7645.
 
Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma.
Appay V., Voelter V., Rufer N., Reynard S., Jandus C., Gasparini D., Lienard D., Speiser D.E., Schneider P., Cerottini J.C. et al., 2007. Journal of Immunotherapy, 30 (2) pp. 240-250. Peer-reviewed.
 
Four functionally distinct populations of human effector-memory CD8+ T lymphocytes.
Romero P., Zippelius A., Kurth I., Pittet M.J., Touvrey C., Iancu E.M., Corthesy P., Devevre E., Speiser D.E., Rufer N., 2007. Journal of Immunology, 178 (7) pp. 4112-4119. Peer-reviewed.
IL-12 controls cytotoxicity of a novel subset of self-antigen-specific human CD28+ cytolytic T cells.
Barbey C., Baumgaertner P., Devevre E., Rubio-Godoy V., Derre L., Bricard G., Guillaume P., Luescher I.F., Liénard D., Cerottini J.C. et al., 2007. Journal of Immunology, 178 (6) pp. 3566-3574. Peer-reviewed.
Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients.
Alves P.M., Viatte S., Fagerberg T., Michielin O., Bricard G., Bouzourene H., Vuilleumier H., Kruger T., Givel J.C., Lévy F. et al., 2007. Cancer immunology, immunotherapy, 56 (11) pp. 1795-1805. Peer-reviewed.
In Vivo Persistence of Codominant Human CD8+ T Cell Clonotypes Is Not Limited by Replicative Senescence or Functional Alteration.
Derré L., Bruyninx M., Baumgaertner P., Devevre E., Corthesy P., Touvrey C., Mahnke Y.D., Pircher H., Voelter V., Romero P. et al., 2007. Journal of Immunology, 179 (4) pp. 2368-2379. Peer-reviewed.
Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer.
Alves P.M., Lévy N., Bouzourene H., Viatte S., Bricard G., Ayyoub M., Vuilleumier H., Givel J.C., Halkic N., Speiser D.E. et al., 2007. Cancer immunology, immunotherapy, 56 (6) pp. 839-847. Peer-reviewed.
 
Sensitive gene expression profiling of human T cell subsets reveals parallel post-thymic differentiation for CD4+ and CD8+ lineages.
Appay V., Bosio A., Lokan S., Wiencek Y., Biervert C., Küsters D., Devevre E., Speiser D., Romero P., Rufer N. et al., 2007. Journal of Immunology, 179 (11) pp. 7406-7414. Peer-reviewed.
 
Tissue homing and persistence of defined antigen-specific CD8+ tumor-reactive T-cell clones in long-term melanoma survivors.
Le Gal F.A., Widmer V.M., Dutoit V., Rubio-Godoy V., Schrenzel J., Walker P.R., Romero P.J., Valmori D., Speiser D.E., Dietrich P.Y., 2007. Journal of Investigative Dermatology, 127 (3) pp. 622-629.
 
A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination.
Speiser D.E., Baumgaertner P., Barbey C., Rubio-Godoy V., Moulin A., Corthesy P., Devevre E., Dietrich P.Y., Rimoldi D., Liénard D. et al., 2006. Journal of Immunology, 177 (2) pp. 1338-1348. Peer-reviewed.
 
Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide.
Appay V., Speiser D.E., Rufer N., Reynard S., Barbey C., Cerottini J.C., Leyvraz S., Pinilla C., Romero P., 2006. European journal of immunology, 36 (7) pp. 1805-14. Peer-reviewed.
 
Dextramers: new generation of fluorescent MHC class I/peptide multimers for visualization of antigen-specific CD8+ T cells.
Batard P., Peterson D.A., Devêvre E., Guillaume P., Cerottini J.C., Rimoldi D., Speiser D.E., Winther L., Romero P., 2006. Journal of immunological methods, 310 (1-2) pp. 136-148. Peer-reviewed.
 
Ex vivo characterization of allo-MHC-restricted T cells specific for a single MHC-peptide complex.
Pittet M.J., Gati A., Le Gal F.A., Bioley G., Guillaume P., de Smedt M., Plum J., Speiser D.E., Cerottini J.C., Dietrich P.Y. et al., 2006. Journal of immunology, 176 (4) pp. 2330-2336. Peer-reviewed.
Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens.
Baumgaertner P., Rufer N., Devevre E., Derre L., Rimoldi D., Geldhof C., Voelter V., Liénard D., Romero P., Speiser D.E., 2006. Cancer Research, 66 (4) pp. 1912-1916. Peer-reviewed.
 
Fluorescence-activated cell sorting and cloning of bona fide CD8+ CTL with reversible MHC-peptide and antibody Fab' conjugates.
Guillaume P., Baumgaertner P., Angelov G.S., Speiser D., Luescher I.F., 2006. Journal of immunology, 177 (6) pp. 3903-3912. Peer-reviewed.
 
Human effector CD8+ T lymphocytes express TLR3 as a functional coreceptor.
Tabiasco J., Devêvre E., Rufer N., Salaun B., Cerottini J.C., Speiser D., Romero P., 2006. Journal of immunology, 177 (12) pp. 8708-8713. Peer-reviewed.
 
Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples.
Appay V., Reynard S., Voelter V., Romero P., Speiser D.E., Leyvraz S., 2006. Journal of immunological methods, 309 (1-2) pp. 192-9. Peer-reviewed.
 
Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity.
Colombetti S., Fagerberg T., Baumgärtner P., Chapatte L., Speiser D.E., Rufer N., Michielin O., Lévy F., 2006. Journal of Immunology, 176 (11) pp. 6560-6567. Peer-reviewed.
 
Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
Bioley G., Jandus C., Tuyaerts S., Rimoldi D., Kwok W.W., Speiser D.E., Tiercy J.M., Thielemans K., Cerottini J.C., Romero P., 2006. Journal of immunology, 177 (10) pp. 6769-6779. Peer-reviewed.
 
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site.
Appay V., Jandus C., Voelter V., Reynard S., Coupland S.E., Rimoldi D., Lienard D., Guillaume P., Krieg A.M., Cerottini J.C. et al., 2006. Journal of Immunology, 177 (3) pp. 1670-1678. Peer-reviewed.
 
The human T cell response to melanoma antigens.
Romero P., Cerottini J.C., Speiser D.E., 2006. Advances in immunology, 92 pp. 187-224. Peer-reviewed.
 
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
van Baren N., Bonnet M.C., Dréno B., Khammari A., Dorval T., Piperno-Neumann S., Liénard D., Speiser D., Marchand M., Brichard V.G. et al., 2005/12. Journal of Clinical Oncology, 23 (35) pp. 9008-9021. Peer-reviewed.
 
Immunological techniques: ex vivo characterization of T cell-mediated immune responses in cancer
Speiser D. E., 2005/08. Current Opinion in Immunology, 17 (4) pp. 419-22.
 
CD4+ T cell responses to SSX-4 in melanoma patients
Ayyoub M., Merlo A., Hesdorffer C. S., Rimoldi D., Speiser D., Cerottini J. C., Chen Y. T., Old L. J., Stevanovic S., Valmori D., 2005/04. Journal of Immunology, 174 (8) pp. 5092-9.
Progress and controversies in developing cancer vaccines.
Slingluff C.L., Speiser D.E., 2005/04. Journal of Translational Medicine, 3 (1) p. 18.
 
Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles
Schwarz K., Meijerink E., Speiser D. E., Tissot A. C., Cielens I., Renhof R., Dishlers A., Pumpens P., Bachmann M. F., 2005/03. European Journal of Immunology, 35 (3) pp. 816-21.
 
Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2
Ayyoub M., Merlo A., Hesdorffer C. S., Speiser D., Rimoldi D., Cerottini J. C., Ritter G., Chen Y. T., Old L. J., Stevanovic S. et al., 2005/01. Clinical Immunology, 114 (1) pp. 70-8.
 
Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma.
Bricard G., Bouzourene H., Martinet O., Rimoldi D., Halkic N., Gillet M., Chaubert P., Macdonald H.R., Romero P., Cerottini J.C. et al., 2005. Journal of immunology, 174 (3) pp. 1709-1716. Peer-reviewed.
 
Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy.
Montes M., Rufer N., Appay V., Reynard S., Pittet M.J., Speiser D.E., Guillaume P., Cerottini J.C., Romero P., Leyvraz S., 2005. Clinical and experimental immunology, 142 (2) pp. 292-302. Peer-reviewed.
 
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.
Speiser D.E., Liénard D., Rufer N., Rubio-Godoy V., Rimoldi D., Lejeune F., Krieg A.M., Cerottini J.C., Romero P., 2005. Journal of Clinical Investigation, 115 (3) pp. 739-746. Peer-reviewed.
 
Recent advances in tumour antigen-specific therapy: in vivo veritas.
Mahnke Y.D., Speiser D., Luescher I.F., Cerottini J.C., Romero P., 2005. International journal of cancer, 113 (2) pp. 173-178. Peer-reviewed.
 
Tinkering with nature: the tale of optimizing peptide based cancer vaccines.
Michielin O., Blanchet J.S., Fagerberg T., Valmori D., Rubio-Godoy V., Speiser D., Ayyoub M., Alves P., Luescher I., Gairin J.E. et al., 2005. Cancer treatment and research, 123 pp. 267-291.
 
Toward improved immunocompetence of adoptively transferred CD8+ T cells.
Speiser D.E., Romero P., 2005. Journal of Clinical Investigation, 115 (6) pp. 1467-1469.
Tumor cell recognition efficiency by T cells.
Speiser D.E., Cerottini J.C., Romero P., 2005. PLoS medicine, 2 (3) pp. e77; author reply e95.
 
Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells
Ayyoub M., Hesdorffer C. S., Metthez G., Stevanovic S., Ritter G., Chen Y. T., Old L. J., Speiser D., Cerottini J. C., Valmori D., 2004/06. Journal of Immunology, 172 (11) pp. 7206-11.
 
An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR
Ayyoub M., Hesdorffer C. S., Montes M., Merlo A., Speiser D., Rimoldi D., Cerottini J. C., Ritter G., Scanlan M., Old L. J. et al., 2004/04. Journal of Clinical Investigation, 113 (8) pp. 1225-33.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Fax. +41 21 692 26 15
Swiss University